Search Results  for '4174.TWO'

Advanced Search

per page
  Report Title Date Provider Type Pgs Price

OBI Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

21 Mar 2015 Reuters Investment Profile 12 $20.00

OBI Pharma (4174 TT, IPO NT$310.0, NR): Commercial success hinges on global phase III study

Event OBI Pharma will be listed on Taipei Exchange on 23 March, with an IPO price of NT$310. It is the largest ever biotech I...

19 Mar 2015 KGI Greater China 8 $81.00

浩鼎 (4174 TT, 承銷價NT$310.0, 未評等): 新穎技術,成功商品化尚待全球臨床三期驗證

重要訊息 浩鼎於3/23上櫃交易,以掛牌價310計算,上櫃後市值約624億台幣,為台灣近年來規模最大的生技股承銷案,籌資超過新台幣62億元,因應持續臨床研究發展所需。 評論及分析 OBI-822/821早期研發史。OBI-822為試驗性抗癌...

19 Mar 2015 KGI Greater China 8 $69.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical compan...

05 Feb 2015 GlobalData 26 $125.00

OBI Pharma Inc. (4174 TT): Pioneer of Active Immunotherapy

OBI is developing therapeutic vaccine OBI-833 for the treatment of new generation of breast cancers. Compared with OBI-822/82...

15 Oct 2014 MasterLink Securities Corporation 8 $81.00

Biotech Sector: It’s About Time to Revisit The New Drug Sector

Taiwan became a Pharmaceutical Inspection Convention and Cooperation Scheme (PIC/s) member on January 1st 2013, which means t...

26 Jul 2013 MasterLink Securities Corporation 5 $46.00